Navigation Links
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
Date:5/1/2008

Duration of Effect in Children and

Adolescents Aged 6 to 17 Years With ADHD

APA Poster Presentation # NR6-008

May 7, 2008; 12:00 p.m. ET

Response to Guanfacine Extended Release in Children and Adolescents Aged 6

to 17 Years With ADHD

APA Poster Presentation # NR6-040

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Approximately 7.8 percent of all school-aged children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of U.S. adults aged 18-44 based on results from the National Comorbidity Survey Replication, a nationally representative household survey, which used a lay-administered diagnostic interview to assess a wide range of DSM-IV disorders. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further i
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
2. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
5. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
6. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
7. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
(Date:3/27/2015)... The Thomas Scattergood Behavioral ... foundation committed to raising its voice to improve ... , The Scattergood Foundation and The Kennedy Forum ... and Practice through the Annual Scattergood Foundation Innovation ... is designed to guide the IBS sufferer through ...
(Date:3/26/2015)... 26, 2015 Elfster.com, the top-rated Secret ... its bucket list generator capabilities to its leading Secret ... to a list that one creates of things to ... movie of the same name. Nowadays many millennials ... memorialize their summer achievements. , "We are greatly expanding ...
(Date:3/26/2015)... TX (PRWEB) March 26, 2015 ... the 32nd annual Dallas Rhinoplasty Symposium and has ... years, reiterated the importance of evidence based medicine (EBM), ... evidence from well conducted research. , "We often hear ... to rhinoplasty, and while we are certainly not trying ...
(Date:3/26/2015)... Franklin, TN (PRWEB) March 26, 2015 ... http://www.healthclick.com . This website is dedicated to providing information ... therapy and occupation therapy community. As a leader ... North American Seminars provided over 200 live and online ... PT OT continuing Education Courses :, A Master Clinicians ...
(Date:3/26/2015)... Francisco, CA (PRWEB) March 26, 2015 The ... These will be on the topics of the DAOM Program ... The DAOM Program Overview Webinar will be hosted by Dr. ... and provide the next steps on how to prepare for ... 12:30 p.m. March 25, March 27, April 1 and April ...
Breaking Medicine News(10 mins):Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:North American Seminars Launches Healthclick.com, a New Mobile Ready Website, Providing CME Course Information to PT, PTA, OT and ATC's 2Health News:North American Seminars Launches Healthclick.com, a New Mobile Ready Website, Providing CME Course Information to PT, PTA, OT and ATC's 3Health News:ACTCM Announces Upcoming Webinars 2
... community outreach program in Delaware has thought of an ... ,Its “Do the Right Thing 4Life” program—supported by AIDS ... well as condoms, to people via the participating barbershops ... by Frank Hawkins, director of education and community outreach ...
... low fat diet into old age, according to a new ... study on nearly 50,000 post-menopausal women in the US, //published ... Association (JAMA), comes to the conclusion that reducing fat intake ... to maintain a stable weight. , ,This discredits ...
... weed, which contains a chemical called cannabinoids which contains a ... “high” effect on the brain. // Due to its high ... be cultivated as an indoor plant under the lamps without ... than 20 times of THC than the one cultivated 30 ...
... WinRho drug, used for treating bleeding disorders. According to Baxter ... to trigger fatal side effects, albeit rarely.// ... States since 1995, and is used to treat a bleeding ... with requisite number of platelets, to form clots. Winrho-related complications ...
... It has been known for long now that Vitamin D ... that Vitamin D supplementation in pregnant// women could lead to ... to a study it has been shown that children whose ... to have weaker bones. ,It is a common ...
... NHS could suffer a big blow if the financial condition ... the Audit Commission.// The prevalence of a weak financial management, ... by district auditors have been accounted for the present condition. ... trusts and hospitals is believed to reach ?75m by the ...
Cached Medicine News:Health News:NHS Audit Commission Warns Possible Financial Collapse In Sussex And Surrey 2
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... potent, naturally secreted estrogen and is the ... In the ovary, estradiol is produced from ... potent estrogen derived from androstenedione. Estrone and ... In men, small amounts of estradiol are ...
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
Clinical marker immunoassay kit for detection of Myoglobin....
Medicine Products: